NCT00975975 · REGISTRY CONDITION SEARCH

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2016-02-26

The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine (investigational therapy) for the prevention of a complication of bone marrow transplantation known as graft-versus-host disease (GVHD). GVHD is a complication in which the cells of the transplanted bone marrow react against organs and tissues.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Grade 3-4 Acute GVHD Rate

→

outcome · POSTED

Time to Neutrophil Engraftment

→

outcome · POSTED

Time to Platelet Engraftment

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Acute myelogenous leukemia: * Second or subsequent remission; patient over 18 yrs of age. * Relapsed after autologous HC transplant, over 18 years of age. * First remission, Philadelphia chromosome + over age 18. * Secondary AML, in first or subsequent remissions. * Acute lymphocytic leukemia: * Philadelphia chromosome + over the age of 50, first or subsequent remission. * Relapse following Autologous HC transplantation, ages over 50. * Second or subsequent remission over the age of 50 * Chronic myelogenous leukemia: * First or second chronic phase over the age of 18. * Accelerated phase over the age of 18. * Must have failed or been intolerant to a standard tyrosine kinase inhibitor. * Chronic lymphocytic leukemia: * Failed nucleoside-based therapy, ages \>18. * Myelodysplasia: * All-risk categories, age greater than 18. * Non-Hodgkin's Lymphoma, less than 76 years of age * Relapsed diffuse aggressive NHL (intermediate and high grade) that fails to achieve CR or PR to conventional salvage chemotherapy. * Aggressive NHL includes diffuse large B cell lymphoma, diffuse mixed small and large cell lymphoma, follicular lymphoma for grade 3 (follicular large cell lymphoma), T or B cell lymphoblastic lymphoma, diffuse small noncleaved (Burkett's or Burkett-like ) lymphoma, mantle cell lymphoma, peripheral T cell lymphoma, anaplastic large cell lymphoma, and other diffuse aggressive lymphomas that are not otherwise classifiable * Aggressive NHL that has relapsed following autologous HCT. Patients that respond to additional treatment for post-transplant relapse are eligible. * Aggressive NHL that does not achieve CR or PR with primary chemotherapy (i.e., primary induction failure). * Low-grade lymphoma refractory to standard therapy, including the following: 1. small cell lymphocytic lymphoma, 2. follicular lymphoma of grades 1 and 2 (follicular small cleaved and follicular mixed small and large cell lymphoma) 3. marginal cell lymphoma, splenic lymphoma), 4. lymphoplasmacytic lymphoma and 5. other lymphomas not otherwise classifiable. * Patients with low-grade lymphoma must have experienced progressive disease after receiving three or more of the following regimens: * alkylator-based therapy (cyclophosphamide/ vincristine/ prednisone) chlorambucil, monoclonal antibody based therapy (e.g., rituximab, Campath-1H, radiolabelled CD20+ antibodies); * nucleoside analog-based therapy (e.g., fludarabine, cladribine).) * Patients with marginal zone lymphoma or gastric MALT type associated with Helicobacter pylori infection must have progressed after receiving appropriate antibiotic therapy as well as three or more regimens as described above * Mantle cell, ages 18-75. * Hodgkin's Disease, ages 18-75. * Relapsed or refractory disease after autologous transplant. * Multiple Myeloma, ages 18-75 * Recurrent disease after two medical therapies * Relapse following autologous transplant * Myelofibrosis, age greater than 18 years * Severe aplastic anemia (refractory to immunosuppressive therapy); age greater than 18 years * Patients with aplastic anemia must have marrow cellularity ≤ 10% plus 2 of the following: 1. Absolute granulocyte count \<500/mm3 2. Corrected reticulocyte count \<1% 3. Untransfused platelet count \<20,000/mm3 on at least 2 occasions 4. Hemoglobin \<9 g/dL (adults) or \< 8 g/dL (children) on at least 2 occasions * Paroxysmal nocturnal hemoglobinuria; age greater than 18 years. * Renal function: creatinine greater than 2.5 * Donor Requirement: * Must have a fully HLA-matched (10 of 10 Antigen matched) related or unrelated donor, eighteen years of age or older, who is capable of undergoing GCSF mobilization and apheresis Exclusion Criteria: * Active CNS disease (the presence of leukemic blasts in the CSF) * Pregnancy or breast-feeding. * Inability to give informed consent. * AST, ALT, total bilirubin \>3x upper limit of normal. * Creatinine \> 2 or creatinine clearance \< 50mL/hr. If patient has a creatinine of \> 2 or creatinine clearance \< 50mL/hr and it is due to the disease process then the patient will not be excluded based on this. * Fractional shortening by echocardiogram not within normal limits per institution or LVEF of \< 40 %. * Pulmonary function: DLCO not within institutional normal limits or DLCO less than 45% of normal predicted, corrected for anemia * Prior allogeneic transplant.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Basiliximab will be given by IV on Day +7 post transplant for recipients of matched unrelated cells. Basiliximab will be given by IV on Day +9 post transplant for recipients of matched related cells.
intervention Names
Drug: Basiliximab
label
Basiliximab
type
EXPERIMENTAL

interventions

arm Group Labels
Basiliximab
description
Basiliximab given 1 time on Day +7 or Day +9.
name
Basiliximab
other Names
Simulect
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 17
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
The percent of patients where a patient experienced a Grade 3 or 4 acute GVHD
measure
Grade 3-4 Acute GVHD Rate
time Frame
Transplant (Day 0) up to 1 year

secondary Outcomes

description
Time to neutrophil engraftment will be analyzed by the Kaplan-Meier method. The time to engraftment of neutrophils is defined as the time from day 0 to the date of the first of three consecutive days after transplantation during which the absolute neutrophils count (ANC) is at least 0.5 x109/l. Patients who did not have neutrophil engraftment before death will be censored at the date of death. The median and 95% confidence intervals will be provided.
measure
Time to Neutrophil Engraftment
time Frame
Transplant (Day 0) up to 1 year
description
Time to platelet engraftment will be analyzed by the Kaplan-Meier method. The time to engraftment of platelets is defined as the time from day 0 to the first of seven consecutive days after transplantation during which the platelet count is at least 20 x109/l without transfusion support. Patients who did not have platelet engraftment before death will be censored at the date of death. The median and 95% confidence intervals will be provided.
measure
Time to Platelet Engraftment
time Frame
Transplant (Day 0) up to 1 year

Full study description

brief Summary: The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine (investigational therapy) for the prevention of a complication of bone marrow transplantation known as graft-versus-host disease (GVHD). GVHD is a complication in which the cells of the transplanted bone marrow react against organs and tissues.
detailed Description: This study is for patients with a blood condition or myelodysplasia (bone marrow disease) which has either not responded to treatment or is not treatable by conventional/routine medical treatments. Bone marrow transplantation is a medical treatment that involves giving high doses of chemotherapy followed by the transplantation of the blood-forming and immune cells from a relative or from a "matched" unrelated person through the National Marrow Donor Program, in an attempt to cure disease in the recipient (the person receiving the donated cells). Nonmyeloablative (bone-marrow preservation) bone marrow transplantation is a relatively new technique in which lower than usual doses of chemotherapy are given before transplantation, in hopes of reducing adverse side effects of the chemotherapy in transplant patients. Nonmyeloablative bone marrow transplantation has several advantages which doctors have determined are beneficial for this condition. This research is being done because the complication of graft-versus-host disease can be bad for a person and there is no completely safe and effective way to prevent this complication. We know that cyclosporine helps but would like to know if the addition of basiliximab, given with cyclosporine, will decrease the incidence and/or severity of graft-versus-host disease after a transplant known as nonmyeloablative or "mini" transplant.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-58b40d12b6a5f57d109a
requested nct id
NCT00975975
primary nct id
NCT00975975
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
989e97b7e4f431acaad3b81cabd0d4e411fa987b95c2524648cc98b3e9624ee5
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-58b40d12b6a5f57d109a
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00975975
occurrences
context exact
NCT00975975
end
11
exact text
NCT00975975
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/805/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
d4cd8a05ec79d6ce42740c399627e2516d42f9e1e37fea4ae887819f798a6fae
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice